FBRXHIGH SIGNALRISK10-K

FBRX's revenue collapsed to near-zero levels while operating losses roughly doubled, indicating severe business deterioration despite positive Phase 1b trial results.

The company appears to have lost substantially all revenue sources while burning cash at an accelerated rate, creating significant financial stress. While the positive celiac disease trial data showing statistically significant benefits represents potential future value, the immediate financial reality suggests urgent need for additional funding or partnerships to sustain operations.

Comparing 2026-03-31 vs 2025-03-28View on EDGAR →
FINANCIAL ANALYSIS

FBRX experienced a catastrophic revenue decline to just $36K from $18M, while operating losses roughly doubled to $70.7M. Despite this deterioration, the balance sheet showed improvement with total assets growing 34.5% to $82.8M and stockholders equity increasing 16.2%, likely reflecting equity raises to fund operations. The company reduced R&D spending by 11.3% to $45.3M, but operating cash burn still increased substantially to $50.9M, indicating mounting financial pressure despite the asset base expansion.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
-99.8%
$18.0M→$36K

Revenue declined 99.8% — significant demand weakness or market share loss warrants investigation.

Net Income
P&L
-95.5%
-$35.5M→-$69.4M

Net income declined 95.5% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-93%
-$36.6M→-$70.7M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Operating Cash Flow
Cash Flow
-65.5%
-$30.7M→-$50.9M

Operating cash flow fell 65.5% — earnings quality concerns; investigate working capital changes and non-cash items.

Total Assets
Balance Sheet
+34.5%
$61.6M→$82.8M

Asset base grew 34.5% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+31.4%
$61.3M→$80.6M

Current assets grew 31.4% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+16.2%
$52.5M→$61.0M

Equity base grew 16.2% — retained earnings accumulation or equity issuance strengthening the balance sheet.

R&D Expense
P&L
-11.3%
$51.1M→$45.3M

R&D spending cut 11.3% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-28
ADDED
Based on the successful completion of the Phase 1 healthy volunteer cohorts, we initiated a patient-based Phase 1b trial in celiac disease in the third quarter of 2024 and a patient-based Phase 1b trial for non-segmental vitiligo in the first quarter of 2025.
In June 2025, we announced positive data in our celiac disease Phase 1b study.
The study enrolled 32 subjects 3:1 randomized (24 on FB102 and 8 on placebo).
Subjects received 4 doses of FB102 (10 mg/kg) and underwent a 16-day gluten challenge.
In addition to safety and tolerability, the study assessed morphologic and inflammatory endpoints along with gluten challenge induced symptoms.
FB102 demonstrated a statistically significant benefit on the composite histological VCIEL endpoint (change from baseline).
The mean VCIEL change from baseline was -1.849 for placebo subjects compared to 0.079 for FB102 treated subjects (p=0.0099).
The change in the density of CD3-positive T cells, or IELs, from baseline was an increase of 13.3 for placebo subjects compared to a decline of 1.5 for FB102 treated subjects (p=0.0035).
Baseline IEL density was 25.6 for the placebo subjects and 23.5 for the FB102 treated subjects.
The mean change in the Vh:Cd ratio from baseline was -0.173 (0.21) for placebo subjects compared to -0.046 (0.09), a 73% improvement for FB102 treated subjects compared to placebo.
REMOVED
Based on the successful completion of the phase 1 healthy volunteer cohorts, we initiated a patient-based trial in celiac disease in the third quarter of 2024.
The trial is currently enrolling and top-line results are expected in the second quarter of 2025.
It is estimated that 1:133 in US (2.5 million people) have celiac disease (Fasano, Arch Intern Med.
FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D).
The global vitiligo treatment market size was estimated at $1.2 billion in 2018 and is projected to reach $1.9 billion by 2026 (Fortune Business Insights).
The global alopecia treatment market was valued at $2.7 billion in 2018, and is projected to reach $3.9 billion by 2026, registering a CAGR of 4.6% from 2019 to 2026 (Allied Mkt Research) .
Type 1 diabetes is caused by autoreactive T Cells destroying insulin-producing pancreatic - cells.
It is estimated that 64,000 people are diagnosed with T1D annually (https://beyondtype1.org/type-1-diabetes-statistics/).
We had approximately $58.4 million in cash, cash equivalents and short-term investments as of December 31, 2024.
3 On November 21, 2024, we issued 4,931,389 shares of our common stock at a purchase price of $5.5520 per share, and 4,615,555 pre-funded warrants to purchase shares of common stock at a purchase price of $5.5510 per pre-funded warrant ("2024 Private Placement").
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →